DE69100364T2 - Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung. - Google Patents

Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.

Info

Publication number
DE69100364T2
DE69100364T2 DE91400163T DE69100364T DE69100364T2 DE 69100364 T2 DE69100364 T2 DE 69100364T2 DE 91400163 T DE91400163 T DE 91400163T DE 69100364 T DE69100364 T DE 69100364T DE 69100364 T2 DE69100364 T2 DE 69100364T2
Authority
DE
Germany
Prior art keywords
myristoyl
phenylalanine
treatment
myristoylation
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE91400163T
Other languages
German (de)
English (en)
Other versions
DE69100364D1 (de
Inventor
Jean-Albert Boutin
Yolande Herve
Georges Remond
Michel Vincent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Servier de Medecine Translationnelle SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of DE69100364D1 publication Critical patent/DE69100364D1/de
Publication of DE69100364T2 publication Critical patent/DE69100364T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE91400163T 1990-01-25 1991-01-25 Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung. Expired - Fee Related DE69100364T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (2)

Publication Number Publication Date
DE69100364D1 DE69100364D1 (de) 1993-10-21
DE69100364T2 true DE69100364T2 (de) 1994-04-21

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE91400163T Expired - Fee Related DE69100364T2 (de) 1990-01-25 1991-01-25 Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.

Country Status (14)

Country Link
US (1) US5164414A (enExample)
EP (1) EP0443891B1 (enExample)
JP (1) JPH0717503B2 (enExample)
AT (1) ATE94387T1 (enExample)
AU (1) AU633395B2 (enExample)
CA (1) CA2034861A1 (enExample)
DE (1) DE69100364T2 (enExample)
DK (1) DK0443891T3 (enExample)
ES (1) ES2060310T3 (enExample)
FR (1) FR2657259A1 (enExample)
IE (1) IE65573B1 (enExample)
OA (1) OA09478A (enExample)
PT (1) PT96571A (enExample)
ZA (1) ZA91574B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
SG11201405413SA (en) 2012-03-30 2014-10-30 Givaudan Sa N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
CN104219964B (zh) 2012-03-30 2016-09-21 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
US10856563B2 (en) 2012-03-30 2020-12-08 Givaudan S.A. N-acyl-amino acid derivatives for improvement of the flavor profile of edible compositions
JP6320367B2 (ja) 2012-03-30 2018-05-09 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化メチオニン誘導体
JP6248092B2 (ja) 2012-03-30 2017-12-13 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化１−アミノシクロアルキルカルボン酸
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
BR122020006518B1 (pt) 2012-03-30 2022-02-22 Givaudan Sa Composição de sabor
KR102496892B1 (ko) * 2012-10-30 2023-02-06 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
EP3057448B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
EP3057446B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3057447B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
WO2015048990A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I

Also Published As

Publication number Publication date
IE65573B1 (en) 1995-11-01
EP0443891B1 (fr) 1993-09-15
EP0443891A1 (fr) 1991-08-28
ES2060310T3 (es) 1994-11-16
ZA91574B (en) 1991-11-27
AU633395B2 (en) 1993-01-28
PT96571A (pt) 1991-10-15
DE69100364D1 (de) 1993-10-21
OA09478A (fr) 1992-11-15
US5164414A (en) 1992-11-17
FR2657259A1 (fr) 1991-07-26
AU6998791A (en) 1991-08-01
FR2657259B1 (enExample) 1994-08-19
DK0443891T3 (da) 1993-12-27
JPH04210916A (ja) 1992-08-03
CA2034861A1 (fr) 1991-07-26
JPH0717503B2 (ja) 1995-03-01
IE910242A1 (en) 1991-07-31
ATE94387T1 (de) 1993-10-15

Similar Documents

Publication Publication Date Title
US5164414A (en) Use of n-myristoyl-(s)-phenylalanine for the treatment of diseases involving myristoylation
DE69031497T2 (de) Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper
DE60033453T2 (de) Verwendung von Depsipeptide und deren Analoge als Immunosuppressiva zur Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Allergien und hyperproliferativer Hautkrankheiten
DE69413085T2 (de) Immunsuppressive Aminomethylen-Peptide
DE4320201A1 (de) Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
PT2132221E (pt) Peptidomiméticos fixados num molde
ZA200107320B (en) Cyclic tetrapeptide derivatives and use thereof as drugs.
EP0635008A1 (de) Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
KR20150027217A (ko) 항진균성 항생 암포테리신 b의 n-치환된 제2 세대 유도체, 및 이의 제조 및 응용 방법
WO1992016549A1 (de) Para-substituierte phenylalanin-derivate
EP0428849A2 (de) Inhibitoren retroviraler Proteasen
DE69506686T2 (de) Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
DE69031340T2 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
DE69220100T2 (de) Retrovirale Protease-Inhibitoren
EP1140989A1 (de) Inhibitoren des integrins alpha(v) beta(6)
EP0432595A1 (de) Neue Peptide, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP0981542B1 (de) Glycokonjugate von 20(s)-camptothecin
EP0929570A1 (de) Modifizierte cytostatika
Santos et al. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity
US20250034194A1 (en) Inhibitors of abnormal phosphorylation and tau protein aggregation
KR20150014910A (ko) 허혈-재관류계 질환의 치료 화합물
DE69119488T2 (de) Disulfat von WS-7622A, Verfahren zur Herstellung und Benutzung
DE60202356T2 (de) Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems
IE900453L (en) New adamantyl comprising tripeptides, derivatives and¹hydrochlorides thereof, their preparation and use
Boutin et al. N‐Myristoyl‐transferase activity in cancer cells: Solubilization, specificity and enzymatic inhibition of a N‐Myristoyl transferase from L1210 microsomes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee